To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.
General Information
DRAVP ID DRAVPe02155
Peptide Name P5 +14
Sequence GGGYSKAQKAQAKQAKQAQKAQKAQAKQAKQAQKAQKAQAKQAKQ
Sequence Length 45
UniProt ID None
Taxon ID None
Source S1 subunit of SARS-CoV-2
Validation Experimentally Validated
Origin Information
Gene Name/ID Not Available
GenBank Not Available
Amino Acid position Not Available
Domain Accession ID Not Available
Nucleotide sequence ID Not Available
Molecular Type Not Available
Chromosomal Position Not Available
Activity Information
Target Organism SARS-CoV
Assay antiviral Assay
Activity Not Avaialble
Hemolytic Activity No hemolysis information or data found in the reference(s) presented in this entry
Cytotoxicity No cytotoxicity information found in the reference(s) presented
Binding Target Not Found
Mechanism Not Available
Structure Information
PDB ID None
Predicted Structure Download No predicted structure available
Linear/Cyclic Cyclic
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Stereochemistry L
Physicochemical Information
Formula C202H351N71O62
Absent amino acids RNDCEGHLFPWOU
Common amino acids A
Mass 4766.45
Pl 10.74
Basic residues 12
Acidic residues 0
Hydrophobic residues 18
Net charge 12
Boman Index 0.9185
Hydrophobicity -1.642
Aliphatic Index 31.11
Half Life
Extinction Coefficient cystines 1490
Absorbance 280nm 0.313
Polar residues 22
Literature Information
Literature 1
Title Heparin-binding Peptides as Novel Therapies to Stop SARS-CoV-2 Cellular Entry and Infection
Pubmed ID 32913137
Reference Molecular pharmacology, 98(5), 612–619.
Author Tavassoly, O., Safavi, F., & Tavassoly, I. (2020).
To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.